KIYATEC

KIYATEC and AACR Joint Abstract at AACR Highlights Use of KIYA-PREDICT™ Drug Response Platform in ACC

Retrieved on: 
Monday, April 4, 2022

The abstract, entitled Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response, evaluates drug response using KIYATECs validated 3D-XPDX adenoid cystic carcinoma (ACC) model based on the KIYA-PREDICT drug response platform.

Key Points: 
  • The abstract, entitled Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response, evaluates drug response using KIYATECs validated 3D-XPDX adenoid cystic carcinoma (ACC) model based on the KIYA-PREDICT drug response platform.
  • KIYATEC Chief Executive Officer Matt Gevaert, Ph.D., said, We are honored to work with ACCRF for patients with this rare condition.
  • Our collaboration represents the mission of KIYATEC to disrupt and inform cancer treatment options by accurately predicting therapeutic tumor response.
  • Jeff Kaufman, Executive Director of ACCRF, said, It has been a pleasure to partner with KIYATEC to develop ex vivo ACC models for drug development and screening.